Literature DB >> 11429269

Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain.

N B Chauhan1, G J Siegel, J M Lee.   

Abstract

The distribution of nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) in substantia nigra pars compacta (SNc) of Parkinson's disease (PD) brains was investigated by immunofluorescence. Cases studied included four 69-77 year old neurologically normal male controls and four 72-79 year old male PD patients. Integrated optical densities (IODs) of immunofluorescence over individual neuromelanin-containing neurons and in areas of neuropil and the number of neurons on H &amp; E stained adjacent sections were quantitated with the use of the BioQuant Image Analyzer. Data were statistically analyzed by ANOVA, including the unpaired two-tailed Student t-test and the Mann-Whitney test. The results showed 55.8% (P<0.0001) dropout of SNc neurons in PD brains compared to age-matched controls. Despite considerable neuronal dropout, immunofluorescent NTFs in the PD brains showed differential reductions that were consistent within the group as compared to age-matched controls: reductions were GDNF, 19.4%/neuron (P<0.0001), 20.2%/neuropil (P<0.0001); CNTF, 11.1%/neuron (P<0.0001), 9.4%/neuropil (P<0.0001); BDNF, 8.6%/neuron (P<0.0001), 2.5%/neuropil. NGF, NT-3 and NT-4 showed no significant differences within surviving neurons or neuropil. Since the depletion of GDNF both within surviving neurons and neuropil was twice as great as that of CNTF and BDNF and since the other NTFs showed no changes, GDNF, of the tested NTFs, is probably the most susceptible and the earliest to decrease in the surviving neurons of SNc. These observations suggest a role for decreased availability of GDNF in the process of SNc neurodegeneration in PD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429269     DOI: 10.1016/s0891-0618(01)00115-6

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  65 in total

Review 1.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Induction of GDNF and BDNF by hRheb(S16H) transduction of SNpc neurons: neuroprotective mechanisms of hRheb(S16H) in a model of Parkinson's disease.

Authors:  Jin Han Nam; Eunju Leem; Min-Tae Jeon; Kyoung Hoon Jeong; Jeen-Woo Park; Un Ju Jung; Nikolai Kholodilov; Robert E Burke; Byung Kwan Jin; Sang Ryong Kim
Journal:  Mol Neurobiol       Date:  2014-05-25       Impact factor: 5.590

3.  Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design.

Authors:  A Park; D Zid; J Russell; A Malone; A Rendon; A Wehr; X Li
Journal:  Parkinsonism Relat Disord       Date:  2013-10-15       Impact factor: 4.891

4.  Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.

Authors:  Yuen-Sum Lau; Gaurav Patki; Kaberi Das-Panja; Wei-Dong Le; S Omar Ahmad
Journal:  Eur J Neurosci       Date:  2011-03-07       Impact factor: 3.386

Review 5.  Mood, memory and movement: an age-related neurodegenerative complex?

Authors:  Ann-Charlotte Granholm; Heather Boger; Marina E Emborg
Journal:  Curr Aging Sci       Date:  2008-07

Review 6.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

7.  Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.

Authors:  Ofelia M Littrell; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

Review 8.  Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Neurochem Int       Date:  2017-02-20       Impact factor: 3.921

Review 9.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.